KVUE Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings has a net margin of 9.82% compared to Kenvue's net margin of -2.77%. Kenvue's return on equity of 9.94% beat Grove Collaborative Holdings's return on equity of -125.41%.

Kenvue has a consensus price target of $24.44, signalling upside risk potential of 14.78%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.50 which suggests that it could grow by 74.83%. Given that Grove Collaborative Holdings has higher upside potential than Kenvue, analysts believe Grove Collaborative Holdings is more attractive than Kenvue.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.81%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 874.64% of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.9B, which are larger than Grove Collaborative Holdings quarterly revenues of $48.3M. Kenvue's net income of $383M is higher than Grove Collaborative Holdings's net income of -$1.3M. Notably, Kenvue's price-to-earnings ratio is 38.71x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.65x versus 0.24x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health has a net margin of 9.82% compared to Kenvue's net margin of 18.82%. Kenvue's return on equity of 9.94% beat Hims & Hers Health's return on equity of 27.83%.

Kenvue has a consensus price target of $24.44, signalling upside risk potential of 14.78%. On the other hand Hims & Hers Health has an analysts' consensus of $26.20 which suggests that it could fall by -29.73%. Given that Kenvue has higher upside potential than Hims & Hers Health, analysts believe Kenvue is more attractive than Hims & Hers Health.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health has a beta of 1.352, suggesting its more volatile than the S&P 500 by 35.191%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.81%. Hims & Hers Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 874.64% of its earnings as a dividend. Hims & Hers Health pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.9B, which are larger than Hims & Hers Health quarterly revenues of $401.6M. Kenvue's net income of $383M is higher than Hims & Hers Health's net income of $75.6M. Notably, Kenvue's price-to-earnings ratio is 38.71x while Hims & Hers Health's PE ratio is 84.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.65x versus 6.84x for Hims & Hers Health. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of 9.82% compared to Kenvue's net margin of -23.21%. Kenvue's return on equity of 9.94% beat The Beauty Health's return on equity of -41.24%.

Kenvue has a consensus price target of $24.44, signalling upside risk potential of 14.78%. On the other hand The Beauty Health has an analysts' consensus of $1.72 which suggests that it could grow by 2.8%. Given that Kenvue has higher upside potential than The Beauty Health, analysts believe Kenvue is more attractive than The Beauty Health.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.81%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 874.64% of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.9B, which are larger than The Beauty Health quarterly revenues of $78.8M. Kenvue's net income of $383M is higher than The Beauty Health's net income of -$18.3M. Notably, Kenvue's price-to-earnings ratio is 38.71x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.65x versus 0.65x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.

Waldencast PLC has a net margin of 9.82% compared to Kenvue's net margin of --. Kenvue's return on equity of 9.94% beat Waldencast PLC's return on equity of -9.22%.

Kenvue has a consensus price target of $24.44, signalling upside risk potential of 14.78%. On the other hand Waldencast PLC has an analysts' consensus of $5.76 which suggests that it could grow by 70.92%. Given that Waldencast PLC has higher upside potential than Kenvue, analysts believe Waldencast PLC is more attractive than Kenvue.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Waldencast PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.81%. Waldencast PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 874.64% of its earnings as a dividend. Waldencast PLC pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.9B, which are larger than Waldencast PLC quarterly revenues of --. Kenvue's net income of $383M is higher than Waldencast PLC's net income of --. Notably, Kenvue's price-to-earnings ratio is 38.71x while Waldencast PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.65x versus 1.42x for Waldencast PLC. Usually stocks with elevated PS ratios are considered overvalued.